Fed Ghali, MD

Fed Ghali, MD, discusses the phase 2 CONSOLIdaTE-01 trial, assessing the role for consolidative local therapy following disease control on EV/P.

Fed Ghali, MD, highlights simulated outcomes of the EV-302 trial when adjusting for use of maintenance avelumab in the control arm.

Fed Ghali, MD, discusses the potential opportunity to de-escalate therapy in patients receiving perioperative EV/pembro.

“If patients are not experiencing a clear clinical benefit for chemotherapy prior to surgery, we need to be really thoughtful about how we use it,” says Fed Ghali, MD.

“It's hard for us, based on our evidence here, to say that neoadjuvant chemotherapy is causal in any way or is resulting in prolonged survival,” says Fed Ghali, MD.